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Previously, we demonstrated that sydnone SYD-1 (3-[4-chloro-3-nitrophenyl]-1,2,3-oxadiazolium-5-
olate) impairs the mitochondrial functions linked to energy provision and suggested that this effect could
be associated with its antitumor activity. Herein, we evaluated the effects of SYD-1 (25 and 50 lM) on rat
hepatocytes to determine its cytotoxicity on non-tumor cells. SYD-1 (25 and 50 lM) did not affect the
viability of hepatocytes in suspension after 1–40 min of incubation. However, the viability of the cultured
hepatocytes was decreased by 66% as a consequence of treatment with SYD-1 (50 lM) for 18 h. Under
the same conditions, SYD-1 promoted an increase in the release of LDH by 19%. The morphological
changes in the cultured cells treated with SYD-1 (50 lM) were suggestive of cell distress, which was
demonstrated by the presence of rounded hepatocytes, cell fragments and monolayer impairment. Fur-
thermore, ﬂuorescence microscopy showed an increase in the annexin label after treatment with SYD-
1 (50 lM), suggesting that apoptosis had been induced in these cells. SYD-1 did not affect the states of
respiration in the suspended hepatocytes, but the pyruvate levels were decreased by 36%, whereas
the lactate levels were increased by 22% (for the 50 lM treatment). The basal and uncoupled states
of respiration of the cultured hepatocytes were inhibited by 79% and 51%, respectively, by SYD-1
(50 lM). In these cells, SYD-1 (50 lM) increased the pyruvate and lactate levels by 84% and 16%,
respectively. These results show that SYD-1 affects important metabolic functions related to energy pro-
vision in hepatocytes and that this effect was more pronounced on cells in culture than those in
suspension.
 2014 Elsevier Ireland Ltd. All rights reserved.1. Introduction
Mesoionic compounds possess several biological activities that
are primarily associated with their chemical structure [1,2]. These
compounds are characterized by positively and negatively charged
regions associated with their polyheteroatomic system that
enables them to interact with biomolecules such as DNA and
proteins. In addition, their net neutral character enables them to
cross biological membranes. The sydnones were the ﬁrst class of
mesoionic compounds synthesized, and they have been associated
with antibacterial [3,4], antitumor [5–7] and antiepileptic activities
[8], among others. In addition, certain sydnones are able to
scavenge free radicals. Sydnone SYD-1 (3-[4-chloro-3-nitro-
phenyl]-1,2,3-oxadiazolium-5-olate) (Fig. 1) has shown important
cytotoxic and antitumor effects in vivo [7]. However, the molecular
Fig. 1. Chemical structure of 3-[4-chloro-3-nitrophenyl]-1,2,3-oxadiazolium-5-
olate (SYD-1).
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mitochondria are involved in the mechanisms of cell death
induction, we previously demonstrated that SYD-1 depresses the
efﬁciency of oxidative phosphorylation and suggested that this
could be related to its antitumor activity [9]. Recently, we also
showed that SYD-1 inhibits the processes associated with oxida-
tive stress, speciﬁcally the iron-induced lipoperoxidation, the oxi-
dation of pyridine nucleotides and the mitochondrial pore
transition [10]. In the same study, the O2 scavenging ability of
SYD-1 was also shown. Because it is especially important that anti-
neoplastic drugs are speciﬁc to tumor cells, the signiﬁcant antitu-
mor activity of SYD-1 and the absence of studies about its effects
on non-tumor cells prompted this evaluation of the effects of
SYD-1 on the metabolic functions of isolated rat hepatocytes.
2. Materials and methods
2.1. Chemicals
D-Mannitol, HEPES, rotenone, FCCP, oligomycin, MTT,
dexamethasone, collagenase types IV and IA, glucagon, insulin, epi-
dermal growth factor (EGF), trypsin, glutamine, penicillin, strepto-
mycin and Dulbecco’s modiﬁed Eagle’s medium (DMEM) were
purchased from Sigma Chemical Co. (St. Louis, MO). All other
chemicals used were of the highest commercially available purity.
SYD-1 was synthesized by the Department of Chemistry at the Fed-
eral Rural University of Rio de Janeiro, Brazil, and its structure was
conﬁrmed by 1H NMR, 13C NMR and mass spectrometry. For use in
this work, SYD-1 was dissolved in DMSO and further diluted with
the assay medium. To validate each assay, duplicate controls with
DMSO were included at the concentrations used in the experi-
ments. The DMSO had no effect on the parameters analyzed.
2.2. Animals
Male Wistar rats (180–200 g) were obtained from the Central
Animal House of the Federal University of Paraná (PR, Brazil). The
animals were housed at 22 ± 1 C under a 12 h-light/12 h-dark
cycle (lights turned on at 8 am) and had free access to standard
laboratory food (Purina) and tap water. The experiments were
conducted following the recommendation of Brazilian Law 6638,
05/11/1979 for the scientiﬁc management of animals, and the
procedures were approved by the Institutional Animal Ethics
Committee (certiﬁcate number 548).
2.3. Isolation, culture and treatment of hepatocytes
The hepatocytes were obtained by monovascular liver perfusion
of Wistar rats, as described previously by [11,12] with modiﬁca-
tions. The male rats were weighed and anesthetized intraperitone-
ally with a mixture of ketamine (60 mg/kg) and xylazine (7.5 mg/
kg). Following laparotomy, 100 lL of sodium heparin (5000 U/
mL) were injected into the abdominal cava vein. The portal and
thoracic cava veins were cannulated, and the liver was perfusedwith Krebs solution (2.399 M NaCl, 96 mM KCl, 24 mM KH2PO4,
24 mM MgSO4, 480 mM NaHCO3 and 1 M HEPES buffer, pH 7.4)
containing 1.3 M CaCl2, 20 mg collagenase (types IA and IV) and
carbogen (95% O2:5% CO2). The liver was excised, and the cells
were released by mechanical action, ﬁltered through 50 lM nylon
membranes and centrifuged at 400 rpm for 5 min at 4 C. Subse-
quently, the cells were centrifuged four times with Krebs solution
supplemented with 20% bovine serum albumin (BSA) and treated
with carbogen. The cells were suspended in high glucose DMEM
supplemented with bovine fetal serum (10%), insulin (100 nM),
glucagon (10 nM), EGF (10 ng/mL), dexamethasone (50 nM), peni-
cillin (100 U/mL) and streptomycin (100 ng/mL). Cell viability
was determined using the Trypan blue (0.4%, w/v) exclusion
method as previously described by Philips [13]. Only the cell sus-
pensions with viabilities higher than 80% were plated (1  106 -
cells/plate on a 60 mm plate) and cultured for further
experiments. Four hours after plating, the medium was replaced
by Hepatozyme with or without SYD-1 (25 or 50 lM) or DMSO
(0.01%), and incubated for 18 h prior to the use in the assays.
2.4. Cellular viability assays
The viability of the suspended hepatocytes incubated with SYD-
1 (25 or 50 lM) for 1, 2, 20 and 40 min was evaluated using the
Trypan blue (0.4%, w/v) exclusion method as previously described
by Philips [13]. The hepatocytes (1  106 cells) were seeded in a
60 cm2-well plate with Hepatozyme medium with or without
SYD-1 (25 or 50 lM) for 18 h. After incubation, the medium was
discarded and a tetrazolium dye (MTT) solution (0.5 mg/mL) was
added. The plates were allowed to incubate at 37 C for 3 h. The
MTT-formazan crystals that formed were dissolved in DMSO and
the absorbance was measured at 540 nm using a microplate reader
[14]. Under the same conditions, the viability of the hepatocytes
was also determined by the release of LDH into the culture med-
ium using an LDH assay kit (Labtest, Lagoa Santa, Brazil) accord-
ing to the manufacturer’s recommended protocol. After SYD-1
treatment, the supernatant was collected and centrifuged at
1200 rpm for 10 min, and the LDH activity was measured. The
results were expressed as LDH activity (U/L).
2.5. Morphological analysis
The morphological changes of the hepatocytes after the
treatments were examined with an Axiovert 40CSFL inverted
microscope with 10 magniﬁcation.
2.6. Annexin V-FITC and propodium iodide double staining
Fluorescence microscopy was performed to determine the cell
apoptosis or necrosis induced by SYD-1. The cells (1  106 cells/
mL) were seeded and incubated with SYD-1 (25 and 50 lM) at
37 C for 24 h. Then, the medium was exchanged for binding buffer
(10 mM HEPES, pH 7.4, 150 mM NaCl, 5 mM KCl, 1 mM MgCl2,
1.8 mM CaCl2) containing 5 lM annexin V-FITC and the cells were
incubated for 10 min. Finally, PI (0.08 lM) was added and images
were immediately captured with an Axiovert 40CSFL inverted
microscope with 10 magniﬁcation.
2.7. Determination of lactate and pyruvate
These assays were performed with both suspended and cul-
tured hepatocytes. For the suspended cells, the hepatocytes
(1  106 cells/mL) were maintained in PBS and incubated for
2 min with SYD-1 (25 and 50 lM) at 37 C under continuous shak-
ing. Then, glucose (5 mM) was added, and samples were collected
at 1, 20 and 40 min. The samples were immediately centrifuged
Fig. 2. Cytotoxic effects of SYD-1. The experimental conditions are described in
Section 2. (A) MTT assay. The cells (1  106) were seeded in a 60 mm-well plate
with or without SYD-1 at concentrations of 25 or 50 lM for 18 h. Then, a
tetrazolium dye (MTT) solution (5 mg/mL) was added. The plates were incubated at
37 C for 3 h. The MTT-formazan crystals that formed were dissolved in DMSO, and
the absorbance was measured at 540 nm using a microplate reader. The results
were expressed as the viability of the control (%). ⁄ and ⁄⁄⁄ denote values
signiﬁcantly different from the control at P < 0.05 and P < 0.0001, respectively. (B)
LDH releasing assay. Under the same conditions as the previous assay, after SYD-1
treatment, the supernatant was collected and centrifuged at 1200 rpm for 10 min.
The LDH activity was measured using an LDH assay kit (Labtest) according to the
manufacturer’s recommended protocol. The results were expressed as LDH activity
(U/L). ⁄⁄⁄ denotes values signiﬁcantly different from the control at P < 0.0001.
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vate were determined in the supernatant. Additionally, the lactate
and pyruvate concentrations in the cultured cells were obtained
from the supernatant of the hepatocyte cultures after incubation
with SYD-1 (25 or 50 lM) for 18 h. The supernatant was collected
and centrifuged (1000 rpm for 1 min), and the lactate and pyruvate
concentrations were measured [15,16].
2.8. Oxygen uptake
The respiration of the intact hepatocytes was measured by
high-resolution respirometry with an Oxygraph-2k (OROBOROS
INSTRUMENTS, Innsbruck, Austria) using two chambers at 37 C
under gentle agitation. The oxygen solubility factor was 0.89 for
the DMEM and, at local barometric pressure (91 kPa), the concen-
tration of oxygen at air saturation was 172.42 lM. The oxygen
uptake of the freshly isolated hepatocytes in suspension (1  106 -
cells) was monitored in DMEM after incubation for 2 min with
SYD-1 (25 or 50 lM). For the measurement of respiration in the
cultured hepatocytes treated with SYD-1 (25 or 50 lM for 18 h),
the cells were detached from the culture dishes with a trypsin
solution and suspended (1  106 cells) in DMEM. The oxygen
consumption was rated in the different states of respiration as pre-
viously described [17–21], and the states were deﬁned as: basal,
oxygen consumption in the absence of inhibitors or uncouplers;
leak, respiration in the presence of oligomycin (2 lg/mL); and
uncoupled, oxygen consumption in the presence of the uncoupler
FCCP (0.5 lM). The oxygen ﬂow in these states was corrected by
the subtraction of non-mitochondrial respiration, which was
obtained after the addition of rotenone (0.5 lM) and antimycin
(3 lg/mL). The results are expressed as the oxygen ﬂow per cells
[pmol/(seg * 1  106 cells)] as media ± SD.
2.9. Protein determination
The protein concentrations were determined using the method
described by Lowry with BSA as the standard [22].
2.10. Statistical analysis
The relevant statistical analysis was performed by analysis of
variance (ANOVA) and by Tukey’s test for average comparison.
The results were expressed as the standard error ± the SEM, and
the values were considered signiﬁcant when P < 0.05.
3. Results
3.1. Cytotoxic effects of SYD-1
SYD-1 (25 and 50 lM) did not affect the viability of hepatocytes
in suspension after 1–40 min of incubation, which was determined
by the Trypan blue assay (data not shown). Two different assays
were used to evaluate the viability of the cultured hepatocytes,
MTT reduction by dehydrogenases from viable cells and LDH
release resulting from cell membrane damage [23,24]. The results
of the MTT assays (Fig. 2A) showed that treatment for 18 h with
SYD-1 at the lowest concentration (25 lM) did not affect hepato-
cyte viability; however, at the highest concentration (50 lM), the
sydnone was able to decrease cell viability by up to 66%. Under
the same conditions, SYD-1 promoted an increase in the release
of LDH by 19% only at the highest concentration (50 lM; Fig. 2B).
3.2. Effects of SYD-1 on hepatocyte morphology
The freshly isolated hepatocytes were morphologically intact, as
visualized by Trypan blue, exhibiting a rounded shape (data notshown). After adhering to the culture plates, these cells acquired
the typical cubic shape often with two nuclei and formed a mono-
layer (Fig. 3A – control). The solvent for SYD-1 (0.01% DMSO) did
not affect the morphology of hepatocytes (Fig. 3B). SYD-1 at the
lowest concentration (25 lM – Fig. 3C) was unable to change the
organization of monolayer; however, some detached rounded cells
were present, suggesting cell distress. The presence of detached
cells was increased at the highest concentration of SYD-1
(50 lM), accompanied by some cell fragments and the disruption
of the cell monolayer in localized areas (Fig. 3D). Although less pro-
nounced, these results are in agreement with the effects of SYD-1
on hepatocyte viability (Fig. 2A and B), which demonstrated that
the compound was cytotoxic at the highest concentration.3.3. Effect of SYD-1 on the induction of hepatocyte death
Because SYD-1 (50 lM) was able to reduce the viability of cul-
tured hepatocytes (Figs. 1 and 2), assays using annexin and PI were
Fig. 3. Effects of SYD-1 on hepatocyte morphology. The experimental conditions are described in Section 2. The rat primary hepatocytes (1  106 cells) were incubated with
SYD-1 (25 or 50 lM) for 18 h. The images were obtained using inverted microscopy and are representative of three independent experiments. The scale shows the real
magniﬁcation. (A) Control (untreated cells); (B) DMSO (cells treated with 0.01% DMSO); (C) cells treated with 25 lM SYD-1; (D) cells treated with 50 lM SYD-1.
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induces the cell death. In these assays, ASA (20 mM) was used as
a positive control of cell death by apoptosis (Fig. 4A). The images
demonstrate that after treatment with the highest concentration
of SYD-1 (50 lM) the ﬂuorescence of annexin increased relative
to the control (Fig. 4D-II and B-II, respectively). The same effect
was not observed after treatment with SYD-1 at the lowest concen-
tration (25 lM; Fig. 4C-II). The increase was also not visualized in
PI ﬂuorescence after treatment with the compound at both concen-
trations (Fig. 4C-III and D-III). These results suggest that SYD-1
induces hepatocyte death by apoptosis and are in accordance with
the results of the viability and morphological assays (Figs. 2 and 3),
which showed the most pronounced effect of the mesoionic com-
pound at 50 lM.3.4. Effect of SYD-1 on hepatocyte respiration
Because SYD-1 decreases the viability and promotes morpho-
logical changes of hepatocytes, it became important to evaluate
whether the compound would also be able to affect the metabolic
functions of these cells. To explore this possibility, the hepatocytes
in suspension and in culture were treated with SYD-1 for 2 min and
18 h, respectively, and the parameters of cell respiration were
determined. These assays were performed with cells that were
not yet permeabilized to approximate the experimental and phys-
iological conditions. Consequently, the reagents used were mem-
brane-permeable inhibitors or uncouplers of mitochondrial
phosphorylation. The oxygen uptake was evaluated in the four
states of respiration [17–21]: basal, leak, uncoupled and inhibited.
The results are shown in Fig. 5, where the solid line represents the
oxygen concentration (lM) and the dashed line represents the
oxygen ﬂow ([pmol/(seg * 1  106 cells)]. In Fig. 5, the basal oxygen
consumption (in the absence of inhibitors or uncouplers) wassigniﬁcantly decreased by oligomycin. The oxygen uptake in the
presence of oligomycin results from the re-entry of protons into
the mitochondrial matrix, characterizing the leak state. The addi-
tion of a classical uncoupler, FCCP, promotes a signiﬁcant increase
in oxygen consumption (uncoupled state). Finally, mitochondrial
respiration was completely inhibited by the addition of rotenone
and antimycin (inhibited state). The values of oxygen ﬂow corre-
sponding to the inhibited state were subtracted from the other
states of respiration so that only the oxygen uptake resulting from
mitochondrial respiration was represented in each state [17–21].
The results of the assays with the hepatocytes in suspension and
in culture were analyzed by the DataLab4 software and are shown
in Fig. 6. The sydnone SYD-1 (25 and 50 lM) did not affect the
states of respiration of the suspended hepatocytes (Fig. 6A). For
the cultured hepatocytes, SYD-1 affects the cellular respiration
only at the highest concentration (50 lM), and it decreased the
oxygen uptake by 79% and 51% for the basal and uncoupled
states, respectively (Fig. 6B). These results corroborate those from
the viability and morphological assays (Figs. 2 and 3), which dem-
onstrated the most pronounced effect of the mesoionic compound
at a concentration of 50 lM.3.5. Effect of SYD-1 on lactate and pyruvate release
The inhibition of respiration by SYD-1 suggests that it could
impair mitochondrial ATP production, which could also result in
the activation of glycolytic pathway. To evaluate this possibility,
the levels of pyruvate and lactate released by these cells were mea-
sured. For the suspension cells, the lactate and pyruvate levels
were determined in the incubation medium at 1, 20 and 40 min
after a previous incubation with SYD-1 (25 and 50 lM) for 2 min.
The reaction was initiated by the addition of 5 mM glucose. The
results are shown in Fig. 7, which shows a decrease in the pyruvate
Fig. 4. Annexin V-FITC and propidium iodide staining of hepatocytes treated with SYD-1. The experimental conditions are described in Section 2. The rat primary hepatocytes
(1  106 cells) were incubated with SYD-1 (25 or 50 lM) for 18 h. The images were captured with an AXIOVERT 40CSFL ﬂuorescence microscope and are representative of
three independent experiments. The scale shows the real magniﬁcation. The annexin V-FITC-positive cells are stained green and the PI-positive cells are stained red. (A)
Positive control – cells treated with 20 mM ASA; (B) control – cells treated with 0.01% DMSO; (C) cells treated with 25 lM SYD-1; (D) cells treated with 50 lM SYD-1. I –
bright phase; II – annexin V-FITC; and III – propidium iodide. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this
article.)
Fig. 5. Representative trace of hepatocyte respiration in an OROBOROS-2K oxygraph. The experimental conditions are described in Section 2. Legends: oligo – oligomycin;
ROT – rotenone; ANT – antimycin. Solid line: oxygen concentration; dashed line: oxygen ﬂow.
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when SYD-1 was present at 25 lM. At the highest concentration
(50 lM), this effect was more pronounced, with a 27% decrease
in the pyruvate levels at 1 min and a 36% decrease at 20 and
40 min (Fig. 7A). Conversely, the lactate levels were increased;
however, this effect was not observed immediately (1 min). This
increase was approximately 21% and 27% after a 20 min incubation
with SYD-1 (25 lM and 50 lM, respectively). For the highestconcentration (50 lM), a 18% increase was observed after a
20 min incubation and a 22% increase was observed after a
40 min incubation (Fig. 7B).
In the cultured hepatocytes, SYD-1 promoted an increase in
both pyruvate (84%; Fig. 7C) and lactate (16%; Fig. 7D) levels,
but only at the highest concentration (50 lM). Taken together,
these results suggest that the mesoionic SYD-1 compound causes
the activation of anaerobic glycolysis in these cells. This effect is
Fig. 6. Effect of SYD-1 on the oxygen uptake of hepatocytes. (A) Hepatocytes in suspension. (B) Hepatocytes in culture. The experimental conditions are described in Section 2.
The cells (1  106) were transferred to the Oroboros 2-K oxygraph chambers, and the oxygen consumption was determined in the absence of inhibitors or uncouplers (basal
state), in presence of oligomycin (leak state) and in the presence of FCCP (uncoupled state). The values represent the mean ± the standard error of six different experiments. ⁄
and ⁄⁄⁄ denote values signiﬁcantly different from the control at P < 0.05 and P < 0.0001, respectively.
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the highest concentration of SYD-1 only.4. Discussion
The signiﬁcant antitumor and cytotoxic effects of SYD-1 have
motivated our studies to elucidate its mechanism of action. We
previously showed that SYD-1 impairs the mitochondrial function
linked to energy provision and suggested that this effect could be
involved in its antitumor activity [9]. Recently, we also demon-
strated that the SYD-1 inhibits processes associated with oxidative
stress [10]. Despite the potential use of SYD-1 as an antitumor
agent, its effects on non-tumor cells were not yet ascertained.
Therefore, in this study, we used rat hepatocytes as model of
non-tumor cells to evaluate the cytotoxicity of SYD-1. Concentra-
tions of 25 and 50 lM were used based on previous experiments
with mitochondria [9,10].
Our experimental strategy included assays with freshly iso-
lated hepatocytes (in suspension) and cultured hepatocytes. Withthe hepatocytes in suspension, SYD-1 did not affect the viability
and respiration for either concentration at all times measured
in the assays (1–40 min). The absence of any effect on hepatocyte
respiration would be unexpected based on the signiﬁcant inhibi-
tion of state 3 in isolated mitochondria that is promoted by SYD-1
[9]. However, the methodological differences must be considered.
The hepatocyte respiration assays were performed without cell
permeation or the addition of exogenous substrate. It is possible
that, in this condition, the access of SYD-1 to the mitochondria
was impaired and therefore, signiﬁcant effects on the respiratory
parameters were not observed. However, the pyruvate and lactate
release from the cells was affected by SYD-1 (25 and 50 lM). The
increased levels of lactate (after 20 and 40 min of incubation) and
the decreased levels of pyruvate (starting after 1 min of incuba-
tion) suggest an activation of anaerobic glycolysis (Fig. 7) in
response to SYD-1 treatment. We previously showed that another
class of the mesoionic compounds, the 1,3,4-thiadiazolium deriv-
atives, are able to insert into the lipid bilayers (liposomes), thus
changing their ﬂuidity [25,26]. Therefore, it is possible that
Fig. 7. Effects of SYD-1 on the pyruvate and lactate levels in hepatocytes. (A) Pyruvate levels in suspended hepatocytes; (B) lactate levels in suspended hepatocytes; (C)
pyruvate levels in cultured hepatocytes; (D) lactate levels in cultured hepatocytes. The experimental conditions are described in Section 2. For A and B, the cells (1  106 cells/
mL) were collected and maintained in PBS at 37 C under constant shaking and were treated with SYD-1 (25 and 50 lM) for 2 min. Then, the reaction was initiated by the
addition of 5 mM glucose. For C and D, the cells (1  106 cells/mL) were seeded and treated with SYD-1 (25 and 50 lM) for 18 h. The pyruvate and lactate concentrations were
measured in the supernatant. The control was the cells in the absence of SYD-1 and in the presence of 0.01% DMSO. For pyruvate, 100% corresponds to t1 = 29.09 ± 0.8;
t20 = 25.67 ± 1.61; t40 = 25.75 ± 1.66. For lactate, 100% corresponds t1 = 34.64 ± 2.3; t20 = 42.0 ± 2.78; t40 = 46.0 ± 3.10. The results are expressed as the mean ± the S.E.M. of ﬁve
different experiments. ⁄, ⁄⁄ and ⁄⁄⁄ denote values signiﬁcantly different from the control at P < 0.05, P < 0.01 and P < 0.0001, respectively.
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inside the hepatocytes that was sufﬁcient to affect the glycolytic
pathway but not impair mitochondrial functions.
In the cultured hepatocytes, only the highest concentration of
SYD-1 (50 lM) was cytotoxic, signiﬁcantly decreasing cell viability
(Fig. 2), promoting marked changes in hepatocyte morphology
(Fig. 3) and decreasing the oxygen uptake in the basal and uncou-
pled states (Fig. 6B). These effects could all be related to the induc-
tion of apoptosis as suggested by the assays with annexin and PI
(Fig. 4). Additionally, in contrast to the observations in the sus-
pended cells, in cultured hepatocytes, SYD-1 (50 lM) promoted
an increase in both pyruvate and lactate levels. The most pro-
nounced effects of SYD-1 on the cultured hepatocytes seemed to
be related to the longer treatment times with SYD-1 (18 h) when
compared with the suspended cells, which were observed for a
maximum of 40 min for the pyruvate and lactate assays. It is pos-
sible that, in cultured hepatocytes, SYD-1 reached a higher concen-
tration than in the suspended cells, which resulted in more
pronounced effects for all analyzed parameters.
The effects of SYD-1 on the cultured hepatocytes may also be
associated with release of nitric oxide. In fact, in experiments per-
formed in our laboratory with the ﬂuorescent DAF-FM probe in a
mitochondria-free system, we veriﬁed the release of
13.69 ± 2.67 nM of NO/min from SYD-1 (3 mM). Also, the addition
of hemoglobin (80 lM) was able to reverse the inhibition of
state 3, promoted by SYD-1 (100 lM) in isolated mitochondria. In
these assays the rate of oxygen ﬂux during state 3
(537.34 ± 29.47 pmol O2/(s *mg protein)) was signiﬁcantly reduced(289.22 ± 23 pmol O2/(s *mg protein)) by addition of 100 lM
SYD-1 as previously described [9]. This inhibition of 53% in
oxygen consumption was partially reversed by hemoglobin addi-
tion (350.07 ± 17.31 pmol O2 mg protein – 33% of inhibition in
comparison to control), reinforcing that NO is released from
SYD-1 structure. Moreover, Chimenti and colleagues (2007)
showed that NOR-3 (50–150 lM), a known NO donor, decreased
the viability and respiration of cultured rat hepatocytes after incu-
bation for 2 h and 40 min, respectively [27]. Another important
aspect of this work is that at the lowest concentration (25 lM)
SYD-1 slightly affected the lactate and pyruvate levels in the
cultured hepatocytes. Likewise, assays with SYD-1 at the same con-
centration in hepatocarcinoma cells (HepG2), also performed in
our laboratory, showed signiﬁcant effects of SYD-1 on the viability
and respiratory parameters of these cells (data not shown). These
results indicate a possible selectivity of SYD-1 (25 lM) for cancer
cells.
In conclusion, SYD-1 (50 lM) reduces the viability, changes the
morphology and impairs certain metabolic functions in cultured
hepatocytes. These effects may be caused by the impairment of
the mitochondrial functions linked to energy provision and are rel-
evant to the advancement of studies proposing the use of SYD-1 as
an antitumor agent.Conﬂict of interest
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